Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis
NCT07193316
·
clinicaltrials.gov ↗
COMPLETED
Status
38
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Liver Cirrhosis
Interventions
OTHER:
no intervention
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS